Good afternoon, everybody. My name is Alex Hammond, and I'm the biopharma analyst here at Wolfe. It is my great pleasure to introduce Protagonist Therapeutics. We have Dinesh Patel, we have Sam, and Matthew. Thank you guys so much for joining us.
Our pleasure.
It's been an absolutely fantastic year for Protagonist. The icotrokinra launch has really been superb. As we think about it, how is it tracking relative to your own internal expectations, and how would you compare this to other IL-23 launches?
Yeah. I think, first and foremost, and by the way, thanks for inviting us. With icotrokinra, as you know, this product is an outcome of a partnership with J&J that started all the way back in 2017, and it's so great to see it come to fruition. First and foremost, I would acknowledge J&J is the best pharma partner a biotech could have. I mean, they are so insightful, so supportive, and the things they are doing with icotrokinra, we could just not have envisioned on our own, obviously. With icotrokinra, there is nothing but enthusiasm, whether you hear it from us or whether you hear it from the J&J executives. The script volumes are really very pleasing, and that's the number that's more than 1,000 words. The drug is approved for psoriasis, for psoriatic arthritis. The first study has been completed.
The primary endpoint has been met. For the other indications, in IBD, as you know, we have just amazing phase II UC data, and there is a good mechanistic rationale for that. Other indications will also pile up, and in J&J's words, also, this is one of the most upbeat launches they have seen in recent years, and this is one of the best drugs that could ever be. All the numbers and all the data and all the anecdotal evidence seems to be very supportive of such bold, bullish statements.
Yeah, true unicorn, right?
Yeah.
Which is representative in the commercials as well.
It is unbelievable.
Exactly. As we also think about the launch, J&J has been saying that 60% of patients are naive to therapy. Where do you expect that to reach steady state, and where are these patients coming from currently?
When they say 60% of the patients are systemic naive, my translation is that these are the patients who are sort of like on very generic topical drugs, so to speak. These are kind of the new pool of patients to, quote-unquote, "targeted therapy," and it is great to see them being the recipients of icotrokinra, right? It kind of then brings icotrokinra into the category of first-line therapy, and that is the most optimal position one would like to have for such a great drug with a proven mechanism, but yet with the scarcity or rarity of being the only oral drug.
How important do you see direct-to-consumer to kind of activate that patient population, and do you think patients understand that clinical data, or do you think it is more so the ease of use that is very important here?
It could be a combination of things. The direct-to-consumer kind of attentiveness is important. We like the ads we are seeing and stuff like that, and so do our friends and family. It has certainly brought more awareness about the drug. It is very unique in a way, right? It is a drug of its kind. I think that kind of increasing the awareness is probably the right thing to do.
I think the DTC ads have been very important. Psoriasis, Skyrizi and Tremfya lately have been fighting month-over-month for who spends the most money in terms of advertising in the pharmaceutical marketplace. I would also say that generally, people underestimate the importance of safety in these kind of treatment choices. Psoriasis is the kind of a disease where you could make different kinds of choices. It's not immediately life-threatening and that sort of thing. It's been great to see that people really wanted to have a really safe oral choice. I mean, this is indicated, you could see how the SOTYKTU launch did when it was only up against Otezla, and there was no icotrokinra at that time, and it didn't meet expectations. I would argue that was largely because of the safety data.
Yeah. The other thing is, like, I mean, in terms of the advertisement, that kind of thing, this is the only ad where I am noticing they are claiming placebo-like safety in the ad itself, which is very unique. Even people who are not in the field of science will be noticing that. Safety is of paramount importance, and especially for chronic indications where you're going to take the drug for a long period of time.
Yeah, that's a great point. Thank you. We also got some ICONIC-ASCEND data last week. Can you walk us through what was shown and what the importance of that data is?
Yeah. I mean, so obviously, the study met the two co-primary endpoints, right? The PASI score as well as the IGA 0/1. It also proved non-inferiority against the injectable, Stelara. This is one of the first examples in the field where an oral drug has established non-inferiority against the established injectable. Of course, it missed the superiority measure, but the explanation for that is very clear. It's, icotrokinra performed exactly the way one would expect to perform in terms of efficacy. It's just that the competitor arm performed exceptionally well above the historical norm. So, there is an explanation for that. But if you dive into the subpopulation analysis and focus on the naive patients, which are basically the patients that would qualify for first-line therapy, that is where statistical significance was achieved, actually, even against Stelara.
And then at last but not least, no surprise, safety as clean as ever before.
Placebo-like?
Yeah.
How important do you think that finding was from either a U.S. access perspective or ex-U.S.?
I think it is probably more important ex-U.S., where reimbursement is a different process. That being said, I think the decisions in Europe will be dominated by the data that is already been produced.
That is what we have heard as well. You have also shown some data today in PSA at ACR, and you also had Stelara there as a comparator arm. Walk us through what the data shows and your excitement for the PSA launch, maybe the patient population size too.
Yeah. I think, in general, patients who have psoriasis, about 30% of that population will transition into psoriatic arthritis at one stage or the other. This data, the psoriatic arthritis study data, we find it very exciting, because it showed improvement both in terms of the arthritic measures as well as obviously the psoriasis measurements, right? But in the arthritic measurements, if you look at the ACR20, ACR50, and ACR70 and if you look at the absolute numbers, I mean, these numbers are, and of course, these are cross-trial comparisons. I mean, these match the numbers of Tremfya and Skyrizi of the world. The data is very powerful in its own right.
Seemed like placebo outperformed a little bit, and we've heard that from other companies.
Yeah. Placebos or comparators, it's the artificiality of that, and when it outperforms, it can create a different kind of outcome or perception in a way. That's why in general, as much as possible, unless it's a pivotal study, then that's a different story. But other than that, it's like the focus should be on what the absolute numbers are with the drug arm.
Can you also kind of walk us through the icotrokinra versus Stelara here, where you actually saw icotrokinra seem to, not in terms of statistical significance, but seem to outperform Stelara. Did that kind of reinforce—
Yeah. It's not statistically significant because the Stelara arm was underpowered. It was just in there for a safety comparison in terms of the design of the study. But as you point out, there was numerical superiority, and I think it's important to see that an oral can hold its own with an injectable.
Yeah, for sure. I guess we're also seeing a biologic-experienced patient population, I believe, next year. So kind of walk us through the differences in that patient population and how you expect icotrokinra to perform.
Of course, in the biologically experienced population, you might expect a little bit lower response rate. The study has a larger number of patients, perhaps taking that into account. But at the end of the day, it will be one of the pivotal studies used to apply for the label claim. So, it's important to change.
Yeah. I think that's a very important point. In the naive population, I think the total study number is about 500+ patients, and in the experienced one, it's, I believe, somewhere around 800+. So, that is a reflection of maybe some of the differences between one study versus the other. Look, I mean, at the end of the day, for IL-23 blockers, their sweet space is in IBD and in psoriasis. As you move more towards arthritic conditions, then clearly, it's IL-17 blockers that come into dominance. So, from a Protagonist perspective, as you know, we have a presence in IL-17 as well, right? That, by the way, of course, it's early stage, but it's fully owned by us.
I was going to say, trying to bring up everything all at once, IBD and IL-17. Let's talk about IL-17 a little bit, but I want to talk about IBD first.
Of course.
Because some of that phase II data that you showed looked absolutely spectacular. I believe we're still waiting on the phase III PCDs and more in 2028, but I believe enrollment has been going really fast. Maybe start out there with what you've heard from J&J on enrollment, and kind of set the lay of the land in terms of potentially phase II to phase III degradation of effect.
Yeah. In a way, I would like to go back even further because it gets back to the genesis of the whole program, right? In 2013, when we started working on the IL-23 pathway, one of the first thing we noticed was, hey, the receptor, IL-23, the receptor is overexpressed in the GI tissue compartment of IBD patients. That kind of gave us a reason to focus on receptor as a target rather than the ligand, which is the target for the antibodies, that kind of thing. At that time, as you can imagine, the focus was just on IBD. Pre-clinically also, we started seeing this evidence that our drug was effective at much lower doses in the colitis models compared to the inflammation models.
Now, fast-forward to the clinical outcome, and as you know, the phase II UC data, 30% clinical remission, that is about as good as it gets. So far, the logic has stayed, and we believe or hope that it will continue to be faithful to us in the phase III outcome as well. But things are looking good, and one thing I can point out is, we get our read from, in terms of the enthusiasm or the pace of enrollment in these ongoing studies, including the UC study, from the statements that J&J makes, and also from watching the dates on clinicaltrials.gov. If you pay attention to what John Reed is saying, it is like, yeah, this is one of the fastest, unprecedented enrollment ever. And just last week, they kind of, on clinicaltrials.gov, mentioned that the enrollment is complete, meaning they are not recruiting anymore.
My back-of-the-envelope math suggests that that means they must have beat the enrollment timeline by at least nine months, if not by a year.
I love how you guys are also using clinicaltrials.gov as much as we are.
Yeah.
All of us. Oh, that is quite funny. That is very—
Well, people forget that moving forward, we're a competitor of ICOTYDE with PN-881, so obviously, J&J takes that into account with respect to how they interact with them.
That makes sense. Before we get to that, I still want to talk about combinations. So you mentioned that 30% efficacy was the most that's been seen with injectables. So how do you think about breaking that efficacy ceiling? What's needed, and is ICOTYDE an asset that you can combine other molecules with?
I think there are a couple of things that come to mind right away. First of all is the acknowledgment that, yes, in IBD, people have tried for a decade or even two decades to come up with that, breaking the ceiling on this 30% clinical remission rates, right? Not successful. So people are moving towards combination therapies or bispecifics and that sort of thing, and that makes all the sense in the world. From my viewpoint, and having studied IBD drugs in our own right at Protagonist as well, what we are observing is, I think it's the induction phase or the initial phase of treatment that needs a stronger approach, and that is where combinations may be favorable.
Once the flares are under control, then in the maintenance setting, and meaning for the rest of your life, so to speak, and which is the largest fragment of treatment, right? Induction is for three to six months. But in the maintenance setting, I think a monotherapy should be fine. But getting back to ICOTYDE could be a wonderful thing, whether it's in a combination setting during the induction phase, and it should definitely be the most preferred pill in a maintenance setting. So, as far as the market share is concerned, that potential, ICOTYDE should win big time in IBD.
Speaking as an old-time oncologist, when you put drugs together, one of the things that you think about is overlapping toxicities. When you have a drug that is relatively non-toxic, it allows it to be combined with just about anything without having to worry about synergistic effect.
Yeah, that is a great point, placebo-like safety. Anything else on ICOTYDE and IBD that you think is particularly interesting that investors might not be appreciating?
I mean, clearly right now, there is so much support, so much interest and attention, and people are paying attention to the weekly script that are being written, things like that. I like to remind myself and others, and by the way, that, hey, this is just in the world of psoriasis, and keep in mind that IL-23 blockers have a future in psoriatic arthritis and ulcerative colitis and Crohn's disease. As these things unfold, Ico numbers could get very big very soon.
I mean, we are at $18 billion peak, so —
Oh
—I have to say we agree with you. Moving on to the IL-17, obviously you guys decided to move forward with a phase II that is being done internally. Walk us through the data that was seen there in terms of the exposure and how it compares to IL-17s that are currently on the market.
Yeah. In terms of the data that we have shared so far in a limited fashion, from that, as you know, we clearly are getting to drug levels, even the trough levels at 24 hour, that are quite above the IC90 benchmark that we have set for this particular project based on our dialogue with the KOLs and all that. So we feel very comfortable about it, and hopefully in the first half of next year, we will be able to share the phase I data in more detail at a medical conference. But based on these findings, we opted for the most aggressive phase II scenario, meaning a fully loaded comprehensive phase II-B study. If you look at our study design, we are evaluating four doses versus a placebo.
It kind of mirrors the phase II FRONTIER study that Takeda did with ICOTYDE, because we want our study to be information-rich so that we can be guided very quickly towards other indications also that could be fetched by IL-17 blockers.
In terms of the additional indications, I think in your slides, is it the second half of 2027 you will maybe make a communication? Or is that a little bit aggressive from a timelines perspective?
No, that is reasonable, and second half of 2027, that's a full six months, so I think we are in that range. That should be fine. We will be staring at the blinded data, but in psoriasis, as you know, if your drug is working, the response rates are pretty high, right? You should be able to make some kind of a definitive judgment call on whether to go for a second indication or not.
Part of our lens at that time is going to be what type of program is going to be most attractive and most valued by a partner, because we would like to eventually have a partner for PN-881 the way we do for icotrokinra, and we would like to create the program that then derives the highest value from that kind of partner.
Can you walk us through how you think about the correct timing from a partnership lens?
Whenever there is a complete meeting of minds and the numbers, the financial numbers, I guess, is the right time. In our experience, it takes several years for the two parties to be familiar with each other, with the asset. That is the main topic, that sort of thing, and at one stage, like I said, a scenario evolves where both parties are in agreement and believe they have created a win-win situation. That was true in our dialogue with J&J back in 2017. That was very true with Takeda when we did ink the rusfertide or MIMRYLO in 2024. So it takes time. And fortunately, we are never going to be careless. We are admitting that, yeah, oral IL-17 will benefit from a partnership at the right stage. It belongs to a pharma.
Now that we have the financial flexibility, we could wait it out a bit longer, and even when a partnership is done, the terms, we could be creating a co-development kind of scenario, right? I mean, as Sam brings up, it's like, hey, if J&J can team up with Blackstone to develop an asset, a pharma partner could team up with Protagonist to develop an asset.
Yeah. No, that makes complete sense. Very excited to see how it turns out. I guess as well, as we think about MIMRYLO.
MIMRYLO.
MIMRYLO.
Yeah.
Thank you.
It's a tongue twister, isn't it?
Yeah. I have been staying away from saying the full name, so thank you for that. The early days of launch have looked pretty fantastic, pretty promising so far. It is pretty interesting. Takeda put out that first, what is it, like 1 billion-2 billion prior to the phase III data coming out, correct?
Yes.
What are you seeing in terms of the no black box from a label perspective, the NCCN guidelines? All of these seem to be lining up for a very strong launch. Is that fair?
Absolutely. I mean, having a clean label, introducing a drug in the PV space that for the first time in the label, you have a fatigue-based improvement, which is huge at a practical level when you get to the patient stage. This is a very unique mechanism. At the heart of PV is uncontrolled hematocrit, and this is the only drug that specifically addresses that. When you add up all these things, I mean, it should have a pretty remarkable future. And in a way, what are the expectations? The benchmark to some degree has also been set up by another transaction in the field. Royalty Pharma paid $100 million for a 1% royalty right on rusfertide, and that was before the approval, so.
Goes to show you, those are smart guys.
Indeed. What you say about the NCCN guidelines, one thing to appreciate is it was given a number one rating, which is the highest level of evidence, but also for high-risk and low-risk patients, which means this mechanism of controlling erythrocytosis specifically, which is novel, should be used all across the spectrum of the disease, which is really important for its eventual—
That is so much in sync with the core observation we made that more than 75% of the patients have uncontrolled hematocrit in spite of their treatment or throughout the spectrum of treatment, right? This patient population prevails in all categories of treatment.
The fatigue lens as well, I think that is very important because patients live this every day. So what have you been hearing from prescribers when you show them the data, or who have kind of—
This goes way back long before launches. If you look back, and we have YouTubes and other things on the internet, you can see of our KOLs presenting our data over time as the data evolves. Very early on, we were getting these dramatic anecdotes of people who, marathon runners who could now run again, academics who could publish again, lawyers who went back to work, and things like that, because not just fatigue, but brain fog and just that, people think, "Oh, they know what it is like to be tired." No, not this type of tired. So it really impairs people's daily lives, and those anecdotes very early on encouraged us to build in the fatigue measures in the phase III, and then they turned out to be correct.
I would encourage everybody to hear some of those Billy Graham-like stories from the KOLs themselves who treated the patients.
You guys also have another shot on goal in PV. You have your own oral hepcidin as well. We have kind of heard anecdotally, or as we have looked at some of the data set, obviously it is a once-a-day oral as compared to a once-weekly. Kind of walk us through the coverage of that asset in terms of efficacy and the benefits you might see on that versus rusfertide.
I think clearly there is the convenience of oral, and as you know, it is fully owned by us, things like that. The drug is going into phase I in the first half of next year, and the beauty is just by looking at the effect on serum iron levels in healthy volunteers, we should be able to obtain the clinical evidence about its effectiveness. Now, with rusfertide, or MIMRYLO rather, it is a once-weekly, but if you look at its PK data or the half-life carefully, it is almost like there is a two, three-day holiday built into that weekly treatment. We will just have to see how the drug performs orally on a once-daily regimen.
The nuances of PKs could be different, but at the end of the day, when we add up everything and whatever we have observed pre-clinically, things like that, we believe it should just perform as well, if not better than rusfertide through a once-daily administration. But clinical data is kind of just around the corner, so we can make more definitive interpretations and statements after we see that data.
We did have a limited number of patients in our clinical experience who wound up on twice-a-week therapy, including in the PACIFIC study where we did it as sort of an induction regimen. What you can see when you give MIMRYLO twice a week is you get a much more potent reduction in the hematocrit. That speaks to the kind of couple two or three-day off period, and that is just talking about, of course, with a pill, we have a lot of flexibility in terms of designing regimens that could either be continuous or intermittent, depending on what.
Yeah, very exciting just using the knowledge that you have built up for our next generation, going after very well-validated targets. With that, turning to obesity, we obviously got the update on your earnings last week that you are kind of moving forward with the oral as compared to the subcu. I would assume that the data made you happy, not sad, but curious some of your thoughts there and what was seen.
Yeah. The SAD data did not make us sad, and it also taught us not to be MAD, meaning we are not doing a MAD study, right? How about that? We have thought this through. Yeah, we really like the data that we saw. In a way, I mean, if we think about it was like, look, we were working on a validated target pathway. The preclinical data looked fantastic, but I just needed still that little bit of clinical evidence that, no, it is actually translating the way we are envisioning it should, and it did. Right away then the decision was like, great, this is all the evidence we care about. Now let us focus on what matters the most, which is the differentiation, and that is how we have pivoted to an oral.
Now, if you think about it, this is probably the most crowded space ever that one would be working on, and yet we are so hell-bent on creating a differentiation. Now, in a wholesome way, our portfolio could look something like that. There is an oral triple, meaning GLP, GIP, GCG, then there will be an oral dual, GLP, GIP, and amylin is the new kid on the block. It may have some advantages. Time will tell. We are also working towards creating an oral amylin mono or polyagonist. So when you add up these three assets, then no matter how crowded the space is, Protagonist is going to stand out as a company with a very unique portfolio in the metabolic space.
One of the things that stood out as we looked at your slides was the four times more potent for your triple G as compared to, I believe, Reta. Walk us through the importance of that as it relates to bioavailability.
When we say four times more potent than retatrutide, I just want to clarify that this is something we saw pre-clinically also, right? It's like when we dose the two drugs, meaning PN-477 and retatrutide on an equimolar basis, we saw higher weight loss with our drug. That's what we are referring to. In the SAD study with the single dose, we have to take it with a grain of salt, but what we found in general is whatever reported effectiveness retatrutide had with a single dose, we are achieving that same level at about four to five times lower dose of our drug. That in turn means that in terms of when we go to oral dosing, right, our demand for exposure levels or the amount of milligram of material needed may turn out to be lower compared to retatrutide. Time will tell.
In a way, all that bodes well in this field particularly, where there is a higher degree of sensitivity around what is the cost and that kind of thing. Of course, with oral peptides, the ultimate challenge is what is the oral bioavailability? But I think the fact that it's more potent may also create lower demand on the extent of oral bioavailability that might be needed. It's going in the right direction.
Yeah, we're really excited to see some of that data.
Yeah.
I believe with that, we've hit our time. Thank you guys so much for joining us. It's been fantastic. Always.
Thank you for having us again. Thank you.